

Supplementary Table S1. Summary of findings of 12 cases of multisystem inflammatory syndrome in children (MIS-C) diagnosed in KK Women's and Children's Hospital from October 2021 to December 2022

<b>Total number of patients, N</b>	<b>12</b>
<b>Demographics</b>	
Median age (IQR) years	7.50 (4.00–9.25)
Male, n (%)	8 (66.67)
Race, n (%)	
Chinese	4 (33.30)
Malay	5 (41.70)
Indian	3 (25.00)
<b>Prior COVID-19 infection, n (%)</b>	
SARS-CoV-2 PCR positive	8 (66.70)
Antigen Rapid Test positive	2 (16.70)
Epidemiological link only	2 (16.70)
SARS-CoV-2 IgG antibody positive	12 (100)
<b>Median interval from COVID-19 infection to onset of MIS-C (IQR), days</b>	25.00 (22.00–29.50)
<b>Inflammatory markers, median (IQR)</b>	
C-reactive protein, mg/L (normal range 0–5)	136.00 (94.25–185.70)
Erythrocyte sedimentation rate, mm/h (normal range 3–15)	59.00 (45.25–89.75), in 10 patients
Procalcitonin, µg/L (normal range ≤0.09)	2.74 (0.88–19.14)
Ferritin, µg/L (normal range 5.3–647.2, depending on age)	565.60 (348.70–420.00)
Lactate dehydrogenase, U/L (normal range 162–452, depending on age)	420.00 (319.00–462.50)
<b>System involvement</b>	
Shock, n (%)	6 (50.00)
Cardiovascular, n (%)	
Abnormal echocardiogram	8 in 11 patients (72.70)
Coronary artery abnormalities	3 in 11 patients (27.80)
Abnormal cardiac function	4 in 11 patients (36.40)
Others: Dilated left ventricle	2 in 11 patients (18.20)

Left ventricular ejection fraction, median (IQR), %	67.00 (55.50–73.50)
Elevated NT-proBNP >500pg/mL, n (%)	8 in 10 patients (80.00)
NT-proBNP, median (IQR), pg/mL,	2558.50 (1118.25–10779.50)
Troponin-I, median (IQR), ng/L	22.00 (10.00–122.00), in 11 patients
Gastrointestinal, n (%)	9 (75.00)
Mucocutaneous/Kawasaki disease features, n (%)	12 (100)
Conjunctivitis	12 (100)
Oral mucosal changes	9 (75.00)
Rash	7 (58.30)
Cervical lymphadenopathy	5 (41.70)
Swollen extremities	6 (50.00)
Neurological, n (%)	5 (41.70)
Headaches	3 (25.00)
Seizures	1 (8.30)
Aseptic meningitis	1 (8.30)
Haematological, n (%)	12 (100)
Coagulopathy (raised D-dimer, elevated PT/aPTT)	12 (100)
Lymphopaenia	11 (91.70)
Median absolute lymphocyte count (IQR), $\times 10^9$ cells/L, (normal range 1.81–5.77 $\times 10^9$ cells/L, depending on age)	0.63 (0.49–0.83)
Thrombocytopaenia	9 (75.00)
Median platelet count (IQR), $\times 10^9$ cells/L, (normal range 140–440 $\times 10^9$ cells/L)	101.50 (90.50–143.25)
Respiratory, n (%)	
Required support or tachypnoeic	4 (33.30)
Required oxygen support only	2 (16.70)
Intubated	1 (8.30)

Renal: elevated creatinine, n (%)	4 (33.30)
<b>Clinical course during hospitalisation</b>	
Required ICU, n (%)	6 (50.00)
Fluid bolus	6 (50.00)
Inotropes	4 (33.30)
Intubated	1 (8.30)
Median length of ICU stay (IQR), days	3.00 (3.00–3.00)
<b>Treatment, n (%)</b>	
IVIg	12 (100)
Steroids	11 (91.70)
High-dose steroids	6 (50.00)
Anakinra	1 (8.30)
Antiplatelet	12 (100)
Aspirin	12 (100)
Clopidogrel	2 (16.70)
Antithrombotic prophylaxis with enoxaparin	6 (50.00)
Median time from admission to diagnosis and treatment (IQR), days	2.00 (2.00–3.00)
Median time from fever onset to treatment (IQR), days	6.00 (4.75–6.00)
Median time from treatment to defervescence (IQR), days	2.00 (2.00–2.00)
Median duration of steroid treatment (IQR), days	42.00 (26.00–49.50)
Median duration of antiplatelet treatment (IQR), days	52.50 (48.50–60.00)
Median duration of antithrombotic prophylaxis (IQR), days	17.00 (8.50–20.25)
<b>Outcome</b>	
Survived, n (%)	12 (100)
Median length of hospitalisation (IQR), days	6.00 (5.00–7.50)
Median time to normalisation of C-reactive protein (IQR), days	
from onset of MIS-C	16.50 (14.00–18.00)
from admission	12.50 (10.75–14.25)
from treatment	10.50 (9.00–13.00)
Median time to normalisation of cardiac function, days (IQR) in 4 patients	

from onset of MIS-C	14.00 (13.00–14.75)
from admission	10.00 (9.00–10.50)
from treatment	8.50 (7.25–9.75)
Patients with documented normal echocardiogram post-discharge, n (%)	11 (91.67)
Median time to normalisation of echocardiogram, days (IQR) in 7 out of 8 patients with abnormal inpatient echocardiograms	
from onset of MIS-C	16.50 (14.00–44.50)
from admission	13.50 (10.00–41.25)
from treatment	10.50 (9.75–40.25)
Patients with abnormal echocardiogram at 6 months post-discharge, n (%)	1 (8.30)

ICU: intensive care unit; IQR: interquartile range; IgG: immunoglobulin G; IVIg: intravenous immunoglobulin; NT-proBNP: N-terminal pro-B-type natriuretic peptide; PCR: polymerase chain reaction; PT/aPTT: prothrombin time/activated partial thromboplastin time; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2